ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy

Paul W Armstrong, Hany Siha, Yuling Fu, Cynthia M Westerhout, Ph Gabriel Steg, Stefan K James, Robert F Storey, Jay Horrow, Hugo Katus, Peter Clemmensen, Robert A Harrington, Lars Wallentin

    39 Citationer (Scopus)

    Abstract

    Ticagrelor, when compared with clopidogrel, reduced the 12-month risk of vascular death/myocardial infarction and stroke in patients with ST-elevation acute coronary syndromes intended to undergo primary percutaneous coronary intervention in the PLATelet inhibition and patient Outcomes (PLATO) trial. This prespecified ECG substudy explored whether ticagrelor's association with vascular death and myocardial infarction within 1 year would be amplified by (1) the extent of baseline ST shift and (2) subsequently associated with fewer residual ST changes at hospital discharge.
    OriginalsprogEngelsk
    TidsskriftCirculation (Baltimore)
    Vol/bind125
    Udgave nummer3
    Sider (fra-til)514-21
    Antal sider8
    ISSN0009-7322
    DOI
    StatusUdgivet - 2012

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy'. Sammen danner de et unikt fingeraftryk.

    Citationsformater